Trial Profile
Ferumoxytol-enhanced Magnetic Resonance Imaging for the Interpretation of Vascular Defects
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Ferumoxytol (Primary)
- Indications Coronary artery disease
- Focus Diagnostic use
- 31 Dec 2022 Planned End Date changed from 27 Feb 2023 to 27 Feb 2024.
- 31 Dec 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.
- 31 Dec 2022 Status changed from recruiting to active, no longer recruiting.